Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

Xilio Therapeutics, Inc.

NASDAQ: XLO · Life Sciences · 2 alerts · CIK 1840233

Share price
$7.70Close, Nov 16
Market cap
$54.4M
Shares outstanding
7.06MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Xilio Therapeutics, Inc. filings on SEC EDGAR ↗

7:35 AM ET 8-K
Financial Results

Xilio Therapeutics Financial Results

Xilio Therapeutics reported financial results for the third quarter ended September 30, 2026, highlighting the dosing of the first patient in its Phase 1/2 trial for XTX501. The company ended the quarter with $45.1 million in cash and cash equivalents, which it expects will fund operations into the second quarter of 2027.

Term
Q3 2026

“In the third quarter, we initiated our Phase 1/2 clinical trial for XTX501, a PD-1/masked IL-2 bispecific that we believe has the potential to become a foundational backbone immunotherapy regimen for solid tumors.”

René Russo, Pharm.D., president and chief executive officer of Xilio

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.